Pharmaceuticals group Shire has reiterated its expectation of good earnings growth in 2012 after a solid first-quarter performance, with total revenues rising by over a fifth on last year.
Total revenues in the three months to March 31st jumped by 21% to $1,172m, from $972m in the same period of 2011. Consensus forecasts were for group revenue of $1,148m. Product sales, which account for the majority of group revenues, increased by 24%.
Shire said that growth was driven particularly by sales of VYVANSE (up 29% to $260m), REPLAGAL (up 28% to $134m), ELAPRASE (up 21% to $126m), VPRIV (up 22% to $72m), FIRAZYR (up 272% to $20m) and INTUNIV (up 63% to $69m). First-quarter revenues also include a $49m contribution from DERMAGRAFT (Q1 2011: $nil) which was acquired with Advanced BioHealing in the second quarter of 2011.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Shire continues to perform strongly with first quarter results in line with our expectations. [...] Our focus on demonstrating value to the healthcare system through meeting the needs of our patients is continuing to deliver," said Chief Executive Officer Angus Russell.
However, adjusted operating profits came in at $362m, up 18% year-on-year but slightly under the consensus forecast of $366m. Shire said that operating expenses increased at a faster rate than total revenues.
"Having made a strong start to the year, we reiterate our confidence in good earnings growth for 2012, while investing in our business to support sustained future growth."
The group expects full-year product sales growth to moderate to the mid-teens range. "Combining this with lower royalties and other revenues, which are expected to be 15% to 25% lower year on year, we are forecasting revenue growth in the low-teens range."
Shares were trading 1.05% higher at 2,023p by 13:15 in London.
BC
-
Google shares bounce on Gemini 2.0 launchGoogle has launched the latest version of its Gemini AI platform, and markets have responded positively. Is it time to buy Google shares?
-
Millions of pension savers could get targeted support under new proposalsThe proposals are part of the FCA’s attempt to tackle the advice gap, after 75% of savers admitted they don’t have a clear plan for their pension
